2010-04-28 12:40:00 CEST

2010-04-28 12:40:42 CEST


REGULATED INFORMATION

English
Okmetic Oyj - Interim report (Q1 and Q3)

OKMETIC INTERIM REPORT 1 JANUARY - 31 MARCH 2010


OKMETIC OYJ  STOCK EXCHANGE RELEASE   28 APRIL 2010 1.40 P.M.


OKMETIC INTERIM REPORT 1 JANUARY - 31 MARCH 2010


JANUARY-MARCH IN BRIEF:

- The net sales amounted to 16.5 (14.8) million euro, up 11.5%.
- Operating profit 0.7 (0.5) million euro, up 29.8%.
- Profit for the period was 1.0 (1.0) million euro.
- Earnings per share for the period were 0.06 (0.06) euro.
- The net cash flow from operations amounted to 2.4 (-0.5) million euro.

PROJECTIONS FOR 2010

The company adjusts its estimate of the net sales for the first quarter. The net
sales are now estimated to rise to 33-35 million euro (previously around 30
million euro). Operating profit and net cash flow from operating activities are
estimated to be clearly positive. The operating profit % of the net sales in the
second quarter of the year is estimated to exceed the level of the first
quarter.

PRESIDENT KAI SEIKKU:"The silicon wafer market continued their recovery started in the second quarter
of 2009. Okmetic´s key customer industries, the semiconductor and sensor
industries, reached the level of the previous wafer volume peak at the beginning
of the year.

In 2010, Okmetic profits from the slowly recovering price level and the cost
savings prepared in 2009. The wafer sales grew by a fifth from the level of the
previous quarter.

When comparing the first quarters in 2009 and 2010, the differences between
sales mixes have to be taken into consideration. A significant proportion of the
result in 2009 was from polysilicon trading and license sales but neither of
these took place in the first quarter."


KEY FIGURES

1,000 euro         1 Jan-  1 Jan-  1 Jan-  1 Jan-
                  31 Mar, 31 Mar, 31 Dec, 31 Dec,
                     2010    2009    2009    2008



Net sales          16,521  14,841  54,361  67,867

Operating profit
before
depreciation
(EBITDA)            2,384   2,241   7,206  15,517

Operating profit      684     527     270   8,476

 % of net sales       4.1     3.6     0.5    12.5

Profit/loss for
the period          1,027   1,001    -513   5,825

Earnings per
share, euro          0.06    0.06   -0.03    0.34

Net cash flow
from operating
activities          2,417    -496   6,315  13,177

Net interest-
bearing
liabilities        -6,795     -56  -4,770    -586

Average number of
personnel during
the period            329     341     337     364


REVIEW IN BRIEF

- The net sales in January-March amounted to 16.5 million euro (14.8 million
euro).
- Okmetic´s sensor wafer sales measured in euros grew around 17 percent from
2009. Semiconductor wafer sales experienced a strong growth compared to the
exceptionally low level of the beginning of 2009. Technology sales remained
clearly behind the level of 2009. The sales comprise solely of silicon crystal
shipments based on long-term agreements.
- Profit for the period was 1.0 million euro (1.0 million euro).
- Earnings per share in January-March were 0.06 euro (0.06 euro).
- The net cash flow from operations in January-March amounted to 2.4 million
euro (-0.5 million euro).
- At the end of the period, the company´s cash and cash equivalents exceeded the
interest-bearing liabilities by 6.8 million euro (0.1 million euro).
- M.Sc. (Econ.) Kai Seikku was appointed Okmetic´s President on 25 January
2010. He started his work at Okmetic immediately.
- On 25 January 2010, the board of directors decided on a directed share issue
of 400,000 shares to the company founded by top management. This company was
allocated a 0.8 million euro loan for the purchase of the shares.
- On 11 February 2010, the board of directors decided on executive management
group´s share-based incentive program for 2010 and 2011.
- The company has repurchased its own shares. At the end of the period, the
company had 186,744 own shares.
- On 11 February 2010, the board of directors has approved of 3.5 million euro
investment in expansion of silicon-on-insulator (SOI) wafer production.
- The net sales are estimated to rise to 33-35 million euro in the first half of
the year. Operating profit and net cash flow from operating activities are
estimated to be clearly positive. The operating profit % of the net sales in the
second quarter is estimated to exceed the level of the first quarter.

MARKETS

Customer industries sensor, semiconductor and solar energy industries

Sensor industry

The development in sensor sales has been influenced by the increased use of
micro sensors in many consumer electronics products. The sale value growth
estimate for the whole year is over 10 percent. The shipments of the first
quarter of 2010 are included in this growth rate. The value of sensor sales in
2010 is expected to reach at least the 2008 level. In terms of quantity, the
sensor shipments will rise to a record high level. (iSuppli)

Several microelectromechanical (MEMS) products are currently being developed
within the sensor segment and they have higher growth rates than other sensors.
Silicon-on-insulator (SOI) technology is a good example of a rapidly growing
sensor manufacturing technology. Okmetic is amongst the pioneering suppliers who
provide these products and services to the sensor industry.

Semiconductor industry

An increase in demand in the semiconductor industry started in the latter part
of 2009 and is continuing. Demand remained strong in the first quarter of the
year.

Monthly sales value in the first quarter was 1.5 times the monthly sales value
in the first quarter of 2009.

In 2010, sales in the semiconductor industry are generally estimated to grow
over 20 percent. Estimates have been revised upwards during the first quarter of
the year. If these estimations become reality, the value of sales in the
semiconductor industry will surpass the level of year 2008.(SIA, SEMI, IC
Insights)

Solar energy industry

Global PV industry is in the middle of rapid volume growth which started in late
2009. Annual demand in 2010 is expected to grow over 15 percent (EPIA).

The price level continues to be low. This causes cost pressures for the entire
industry and the level of new investments is estimated to stay low. Governmental
decisions on subsidies have a significant impact on the solar energy industry.
This brings certain insecurity to the development of the market.

Silicon wafer industry

The market development of the silicon wafer industry is monitored in terms of
surface area. According to the report published in February by SMG, the group of
silicon wafer suppliers in SEMI, the volume of wafer shipments in the silicon
wafer industry in the last quarter of 2009 soared up to 2,109 million square
inches, which was 17 percent higher than the shipment volume in the previous
quarter. The wafer market is estimated to have remained strong during the first
quarter of the year.

The demand volume for silicon wafers follows the shipment volumes of customer
industry, so the volumes in silicon wafer industry are also expected to continue
its recovery. Along with the increase in the semiconductor and sensor
industries, the demand in the silicon wafer market will remain strong in the
first half of 2010.

Okmetic

The sensor and semiconductor wafer sales in the first quarter have remained
strong and grown by a fifth compared to the previous quarter. Okmetic has
succeeded to increase its market share in the product areas which are important
to the company. Silicon crystal shipments based on long-term agreements and
negotiations for new technology sales contracts were continued.

PROJECTIONS FOR THE NEAR FUTURE

Semiconductor and sensor wafer shipments are estimated to continue their growth
during the second quarter of the year. As previously announced, around 12
million euro silicon mono crystal sales, which are included in technology sales,
have already been agreed with customers for year 2010.

The net sales are estimated to rise to 33-35 million euro in the first half of
the year. Operating profit and net cash flow from operating activities are
estimated to be clearly positive. The operating profit % of the net sales in the
second quarter is estimated to exceed the level of the first quarter.

EVENTS AFTER THE INTERIM REPORT PERIOD

In April, the company has prematurely repaid 1.2 million euro worth of
installments towards its long-term interest-bearing loans. After the
installments the group´s loan is 1.0 million euro.

The company is a part of electronics component value chain in which goods are
mainly transported by air freight. At the end of April, a volcano erupted in
Iceland and this affects flights. The eruption is not estimated to have a
significant impact on Okmetic´s profit-making opportunities provided that the
flight restrictions issued in April are not extended.

SALES

Okmetic´s net sales increased by 11.3 percent (5.0%) from the previous year,
amounting to 16.5 million euro (14.8 million euro). The growth of net sales was
supported by the rapid global recovery of the semiconductor industry. Okmetic´s
market share grew in the product areas which are important to the company.

Sales per customer area

                 1.1.-   1.1.-    1.1.-    1.1.-
               31.3.10 31.3.09 31.12.09 31.12.08



Sensors            42%     38%      41%      37%

Semiconductors     42%     18%      31%      38%

Technology         16%     44%      28%      25%


The sensor wafer shipments were around 20 percent greater than in the
corresponding period last year. The proportion of sensor wafer sales of
Okmetic´s total sales grew.

General recovery in semiconductor sales had an effect especially in the sale of
semiconductor wafers. The shipment volume for these wafers about tripled
compared to the corresponding period in the previous year. The global market
price for semiconductor wafers is on the rise.

Technology sales have clearly been held back by the current economic situation.
After the major crystal sales agreements signed towards the end of last year and
to be realised in 2010, negotiations by Okmetic to be involved in new projects
have not lead to any agreements so far. Net sales were far from the figures of
the previous year.

Sales per market area

                1.1.-   1.1.-    1.1.-    1.1.-
              31.3.10 31.3.09 31.12.09 31.12.08



North America     40%     36%      37%      39%

Europe            29%     39%      33%      33%

Asia              31%     25%      30%      28%


Traditionally Okmetic has strong market positions in the North America and
Europe. The proportion of Asia of the total net sales continued to increase in
the beginning of 2010, reflecting the general change of focus in global economy.

PROFITABILITY

In January-March, Okmetic group´s operating profit was 0.7 million euro (0.5
million euro). The operating profit accounted for 4.1 percent (3.6%) of net
sales. The profit for the period amounted to 1.0 million euro (1.0 million
euro). Earnings per share were 0.06 euro (0.06 euro).

FINANCING

The group´s financial situation is good. The net cash flow from operations
amounted to 2.4 million euro (-0.5 million euro).

The group´s interest-bearing liabilities amounted to 2.5 million euro (17.4
million euro) at the beginning of the year.

Okmetic Oyj granted 0.9 million financing to the top management and the company
founded by the top management to the repurchase of Okmetic´s own shares.

At the end of the period, cash and cash equivalents amounted to 9.3 million euro
(17.4 million euro). On 31 March 2010, the group´s cash and cash equivalents
exceeded the interest-bearing liabilities by 6.8 million euro (on 31 March 2009
liabilities were 0.1 million higher than cash and cash equivalents).

Return on equity amounted to 8.4 percent (7.9%). The group´s equity ratio was
76.3 percent (65.4%). Equity per share was 2.97 euro (3.06 euro).

INVESTMENTS

Okmetic´s capital expenditure amounted to 0.0 million euro (0.8 million euro).
On 11 February 2010, the board of directors decided on a 3.5 million euro
equipment investment in expansion of silicon-on-insulator (SOI) wafer production
scheduled in financial year 2010. The investment reinforces Okmetic´s position
as the sensor wafer market leader.

PRODUCT DEVELOPMENT

The company expensed 0.5 million euro (0.6 million euro) in long-term product
development projects during the financial period. Product development costs
accounted for 2.9 percent (3.9%) of net sales. Product development costs have
not been capitalised.
Product development has been allocated to sensor wafers that are important to
Okmetic.

PERSONNEL

On average, Okmetic employed 329 people (2009: 338). At the end of the period,
294 of the group´s employees worked in Finland, 32 in the US and three in Japan.

The personnel incentive scheme concerning company management and clerical
workers has been revised. On 25 January 2010, as a part of the revision the
board of directors decided on a directed share issue of 400,000 shares at the
share price of three euro to the company founded by the top management. On 11
February 2010, the board of directors decided on executive management group´s
share-based incentive program for 2010 and 2011 as a part of the group´s
incentive and commitment plan. The shares potentially assigned as bonuses will
be the company´s own shares repurchased in the stock market, so that the
incentive scheme does not have a weakening impact on the number of shares. At
the same time the incentive scheme aimed at the clerical workers was revised.

OKMETIC´S CORPORATE GOVERNANCE

Okmetic Oyj's annual general meeting, which was held on 7 April 2010, adopted
the financial statements for 2009 and discharged the members of the board of
directors and the presidents from liability. A dividend of 0.05 euro per share
will be distributed for 2009. The dividend was paid on Monday 19 April 2010.
Moreover, the general meeting approved the proposal of the board of directors to
amend the articles of association and to authorise the board of directors to
decide on the repurchase and/or the acceptance as pledge of the company´s own
shares and as well as on the issuance of the shares.

It was decided that there would be five members on the company's board of
directors. Tapani Järvinen, Hannu Martola, Pekka Salmi and Henri Österlund were
re-elected as members of the board of directors until the end of the next annual
general meeting, and Esa Lager was elected as a new member. The board of
directors elected Henri Österlund as its chairman and Esa Lager as its deputy
chairman in its organisation meeting held immediately after the annual general
meeting.

Authorised Public Accountant PricewaterhouseCoopers Oy was elected as auditor,
with APA Mikko Nieminen having the principal responsibility.

Authorisations given to the board of directors and other decisions of the annual
general meeting have been notified in a stock exchange release published on 7
April 2010.

M.Sc. (Econ.) Kai Seikku was appointed Okmetic´s President on 25 January 2010.
He started his work at Okmetic immediately.

BUSINESS RISKS IN THE NEAR FUTURE

The most significant factors causing uncertainty for Okmetic´s business are
related to the sensitivity of semiconductor wafer demand to economic
fluctuations, the rapid and strong changes in the market situation, limited
price negotiation power due to company´s small world market share, exchange rate
risk, electricity price risk, contract manufacturing in Asia and uninterrupted
flow of all materials.

The company risks and uncertainty factors are dealt more profoundly in the
company´s annual report of 2009.


SHARES AND SHAREHOLDERS

On 31 March 2010, Okmetic Oyj's paid-up share capital, as entered in the Finnish
trade register, was 11,821,250.00 euro. The share capital is divided into
17,287,500 shares. The shares have no nominal value attached. Each share
entitles its holder to one vote at general meetings. The company has one class
of shares.

On 25 January 2010, the board of directors decided on a directed share issue of
400,000 shares to Okmetic Management Oy founded by Okmetic´s President and
Deputy to the President. The issue of shares was subscribed for in its entirety.
New shares were entered in the Finnish trade register on 4 March 2010.

SHARE PRICE DEVELOPMENT AND TRADING

A total of 2.8 million shares (1.1 million shares) were traded between 1 January
and 31 March 2010, representing 16.3 percent (6.6%) of the weighted average of
share total of 17.0 million (16.9 million) during the period. The lowest
quotation of the period was 2.98 euro (1.81 euro), and the highest 3.51 euro per
share (2.98 euro), with the average being 3.18 euro (2.16 euro). The closing
quotation for the period was 3.41 euro (2.00 euro). At the end of the period,
the market capitalisation amounted to 59.0 million euro (33.8 million euro).

DISCLOSURE OF HOLDINGS

Okmetic Oyj has received notification on 4 March that due to Okmetic´s share
issue the total holdings of foreign Accendo Capital Sicav SIF´s correspond on 4
March 2010 to 14.81 percent of Okmetic´ share capital and voting rights.

OWN SHARES

On 11 February 2010, the board of directors has decided on a purchase scheme of
the company´s own shares, based on the authorisation given at the extraordinary
general meeting on 6 November 2008. It was decided that the aggregate number of
shares repurchased will not be more than 280,000. The repurchase started on 18
February 2010 and ended on 6 April 2010.

At the end of the reporting period, the company owned 186,744 of its own shares.
This is approximately 1.2 percent of Okmetic´s all shares and votes. At this
point, a total of 610,444 euro was used to acquire shares.

The repurchased shares may be used in developing the company's capital
structure, as compensation in possible corporate acquisitions or in other
business arrangements, as part of the company's incentive plan or transferred or
cancelled in other ways.



CONDENSED FINANCIAL STATEMENTS AND TABLES 1 JANUARY - 31 MARCH 2010 (unaudited)

ACCOUNTING POLICIES

These interim financial statements have been prepared in accordance with IAS
34, Interim Financial Reporting.

In preparing these interim financial statements, Okmetic has followed the same
accounting policies as in the financial statements for 2009 except for the
effect of changes required by the adoption of the new or revised standards and
interpretations effective in 2010. Of these the most relevant are:

-IFRS 3 (revised), Business Combinations.
-IAS 27 (revised), Consolidated and Separate Financial Statements.

The management´s view is that the adoption of the standards and interpretations
mentioned above has no significant effect on the figures presented for the
reporting period.

Okmetic Management Oy, founded and owned by Okmetic´s top management, has been
added as a new company into the consolidated financial statements due to the
shareholders´ agreement signed between Okmetic Management Oy and Okmetic Oyj.

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

1,000 euro                                   Jan 1-  Jan 1-  Jan 1-
                                            Mar 31, Mar 31, Dec 31,
                                               2010    2009    2009



Net sales                                    16,521  14,841  54,361

Cost of sales                               -13,826 -12,420 -47,883

Gross profit                                  2,695   2,421   6,478

Other income and
expenses                                     -2,011  -1,894  -6,208

Operating profit/loss                           684     527     270

Financial income and
expenses                                        234     291    -860

Profit/loss before tax                          918     818    -590

Income tax                                      109     184      77

Profit/loss for
the period                                    1,027   1,001    -513



Other comprehensive income:

Translation differences                         364     246    -220



Total comprehensive
income for the
period                                        1,390   1,247    -733



Profit/loss for the period attributable to:

Equity holders of the
parent company                                1,027   1,001    -513



Total comprehensive income attributable to:

Equity holders of the
parent company                                1,390   1,247    -733



Basic and diluted
earnings per
share, euro                                    0.06    0.06   -0.03


CONDENSED CONSOLIDATED BALANCE SHEET

1,000 euro                                               Mar 31, Mar 31, Dec 31,
                                                            2010    2009    2009



Assets



Non-current assets

Property, plant and
equipment                                                 31,847  38,480  33,174

Other receivables                                          3,568   4,650   3,398

Total non-current
assets                                                    35,414  43,130  36,572



Current assets

Inventories                                                7,806   8,504   7,164

Receivables                                               12,586  10,085  10,950

Cash and cash
equivalents                                                9,316  17,410   7,307

Total current assets                                      29,709  35,999  25,422



Total assets                                              65,123  79,129  61,994



Equity and liabilities

Equity

Equity attributable to equity holders of the parent
company

Share capital                                             11,821  11,821  11,821

Other equity                                              37,700  39,815  36,921

Total equity                                              49,522  51,637  48,742



Liabilities

Non-current liabilities                                    3,668  13,854   3,143

Current liabilities                                       11,934  13,638  10,109

Total liabilities                                         15,602  27,492  13,252



Total equity and
liabilities                                               65,123  79,129  61,994



CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

1,000 euro                             Jan 1-  Jan 1-  Jan 1-
                                      Mar 31, Mar 31, Dec 31,
                                         2010    2009    2009



Cash flows from operating activities:

Profit/loss before tax                    918     818    -590

Adjustments                             1,675   1,454   7,183

Change in working
capital                                  -263  -2,960     289

Financial items                            62     193    -567

Tax paid                                   26       -      -1

Net cash from operating
activities                              2,417    -496   6,315



Cash flows from investing activities:

Proceeds from investing
activities                                  -     641     641

Capital expenditure                       -23    -793  -1,694

Net cash used
in investing
activities                                -23    -152  -1,053



Cash flows from financing activites:

Repayments of long-term
borrowings                                  -       - -14,823

Payments of
finance lease
liabilities                               -17     -37    -117

Share issue                             1,200       -       -

Repurchase of
own shares                             -1,810       -       -

Dividends paid                              -       -    -844

Net cash used
in financing
activities                               -627     -37 -15,784



Increase(+)/
decrease(-) in
cash and cash
equivalents                             1,767    -685 -10,523

Exchange rate changes                     242     121    -145

Cash and cash
equivalents at
the beginning
of the
period                                  7,307  17,975  17,975

Cash and cash
equivalents
at the end of
the period                              9,316  17,410   7,307




CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

    Equity attributable to equity holders of parent company

               Share  Share  Reserve Trans- Retai-     Total
               capi-   pre-  for in- lation  ned      equity
                 tal   mium   vested diffe-  ear-
1,000 euro                     unre- rences nings
                            stricted
                              equity

Balance
at 31 Dec,
2009          11,821 20,045        -    415 16,461    48,742

Profit/loss
for the
period                                       1,027     1,027

Translation
differences                             364              364

Total
comprehensive
income for
the period                              364  1,027     1,390

Share issue                    1,200                   1,200

Repurchase
of own
shares                                      -1,810    -1,810

Total
trans-
actions
with owners                    1,200        -1,810      -610

Balance
at 31 Mar,
2010          11,821 20,045    1,200    778 15,677    49,522



Balance
at 31 Dec,
2008          11,821 20,115        -    635 17,818    50,389

Profit/loss
for the
period                                       1,001     1,001

Translation
differences                             246              246

Total
comprehensive
income for
the period                              246  1,001     1,247

Balance
at 31 Mar,
2009          11,821 20,115        -    881 18,819    51,637




CHANGES IN PROPERTY, PLANT AND EQUIPMENT

1,000 euro               Jan 1-  Jan 1-  Jan 1-
                        Mar 31, Mar 31, Dec 31,
                           2010    2009    2009



Carrying amount at the
beginning of the period  33,174  38,848  38,848

Additions                    21   1,046   1,448

Disposals                     -       -       -

Depreciation             -1,699  -1,713  -6,936

Exchange differences        351     299    -187

Carrying amount at the
end of the period        31,847  38,480  33,174


CHANGES IN FINANCIAL LIABILITIES

1,000 euro               Jan 1-  Jan 1-  Jan 1-
                        Mar 31, Mar 31, Dec 31,        2010    2009    2009



Carrying amount at the
beginning of the period   2,538  17,389  17,389

Repayment of loans from
financial institutions        -       - -13,806

Repayments of
subordinated
loans                         -       -    -928

Changes in finance
lease
liabilities                 -17     -35    -117

Carrying amount
at the end of
the period                2,521  17,354   2,538




COMMITMENTS AND CONTINGENCIES

1,000 euro                             Mar 31, Mar 31, Dec 31,
                                          2010    2009    2009



Loans secured
with collaterals                         1,000  13,333   2,500

Collaterals                              8,073  24,964   8,073

Off-balance
sheet lease
commitments                                121     129      83



Capital commitments                        318     259     111



Nominal values of derivative contracts

Currency
forward
agreements                                 707   1,952   1,385

Electricity derivatives                  2,245   2,859   2,520

Interest rate swaps                      6,429   7,071   6,429



Fair values of derivative contracts

Currency forward
agreements                                 -35      73      -4

Electricity derivatives                   -302    -808    -258

Interest rate swaps                       -162     -23     -49


The contract price of the derivatives has been used as the nominal value of the
underlying asset. Derivative contracts are for hedging.

RELATED PARTY TRANSACTIONS

Key management compensation during the period under review amounted to 361,000
euro (300,000 euro).

Okmetic Management Oy, owned by Okmetic´s top management, and one of its
founders have been granted a loan of 0.9 million euro by Okmetic Oyj.


KEY FIGURES SHOWING FINANCIAL PERFORMANCE

1,000 euro                Jan 1-  Jan 1-  Jan 1-
                         Mar 31, Mar 31, Dec 31,
                            2010    2009    2009



Net sales                 16,521  14,841  54,361

Change in net sales
compared to the previous
year´s period, %            11.3   -12.9   -19.9

Export and foreign
operations share of net
sales, %                    95.6    95.5    95.4

Operating profit before
depreciation (EBITDA)      2,384   2,241   7,206

    % of net sales          14.4    15.1    13.3

Operating profit             684     527     270

    % of net sales           4.1     3.6     0.5

Profit/loss before tax       918     818    -590

    % of net sales           5.6     5.5    -1.1

Return on equity, %          8.4     7.9    -1.0

Return on investment, %      8.3     6.1     0.0

Non-interest-bearing
liabilities               13,081  10,138  10,715

Net interest-bearing
liabilities               -6,795     -56  -4,770

Net gearing ratio %        -13.7    -0.1    -9.8

Equity ratio, %             76.3    65.4    78.9

Capital expenditure           21   1,046   1,448

    % of net sales           0.1     7.0     2.7

Depreciation               1,699   1,713   6,936

Research and development
expenditure 1)               487     574   2,134

    % of net sales           2.9     3.9     3.9





Average number of            329     341     337
personnel during
the period

Personnel at the end of
the period                   329     338     327


1) Research and development expenditure has been presented in gross figures and
only long-term projects based on research program have been taken into account.

KEY FIGURES PER SHARE

Euro                       Mar 31,    Mar 31,    Dec 31,
                              2010       2009       2009



Earnings per
share basic
and diluted                   0.06       0.06      -0.03

Equity per share              2.97       3.06       2.89

Dividend per share               -          -       0.05

Dividends/earnings, %            -          -     -164.7

Effective dividend
yield, %                         -          -        1.6

Price/earnings(P/E)           56.0       33.7     -105.4



Share performance
(Jan 1-)

Average trading price         3.18       2.16       2.54

Lowest trading price          2.98       1.81       1.81

Highest trading price         3.51       2.98       3.20

Trading price
at the end
of the period                 3.41       2.00       3.20

Market capitalization
at the end of the
period,1,000 euro           58,950     33,775     54,040


Trading volume (Jan 1-)

Trading volume,
transactions             2,774,164  1,122,059  4,316,320

In relation to weighted
average number of
shares, %                     16.3        6.6       25.6

Trading volume, euro     8,828,923  2,426,463 10,957,275

The weighted average
number of shares during
the period under review
adjusted by the share
issue                   17,011,944 16,887,500 16,887,500

The number of shares at
the end of the period
adjusted by the share
issue                   17,287,500 16,887,500 16,887,500


When calculating earnings per share (EPS) and equity, Okmetic´s own shares in
its possession and Okmetic´s shares owned by Okmetic Management Oy are deducted
from the amount of shares.

QUARTERLY KEY FIGURES

                          10-12/10 7-9/10 4-6/10 1-3/10



Net sales                                        16,521

  Compared to previous
  quarter%                                         19.6

Operating profit/loss                               684

  % of net sales                                    4.1

Profit/loss before tax                              918

  % of net sales                                    5.6



Net cash flow generated
from:
Operating activities                              2,417

Investing activities                                -23

Financing activities                               -627

Increase/decrease in cash
and cash equivalents                              1,767



Personnel at the end of
the period                                          329


                            10-12/09 7-9/09 4-6/09 1-3/09



Net sales                     13,812 12,171 13,538 14,841

  Compared to previous
  quarter %                     13.5  -10.1   -8.8   -5.8

Operating profit                -197   -748    688    527

  % of net sales                -1.4   -6.1    5.1    3.6

Profit/loss before tax          -196 -1,257     46    818

  % of net sales                -1.4  -10.3    0.3    5.5



Net cash flow generated
from:
Operating activities           1,858    192  4,761   -496

Investing activities             -28    -87   -786   -152

Financing activities         -11,821    -22 -3,905    -37

Increase/decrease in cash
and cash equivalents          -9,991     83     70   -685



Personnel at the end of the
period                           327    335    343    338




DEFINITIONS OF KEY FINANCIAL FIGURES



Operating profit before depreciation  = Operating profit + depreciation
(EBITDA)



Return on equity, % (ROE)             = Profit/loss for the period from
                                        continuing operations x 100/
                                       -----------------------------------------
                                        Equity(Average for the period)



Return on investment, % (ROI)         = (Profit/loss before tax + interest and
                                        other financial expenses) x 100/
                                       -----------------------------------------
                                        Balance sheet total - non-interest
                                        bearing liabilities(average for the
                                        period)



Equity ratio, %                       = Equity x 100/
                                       -----------------------------------------
                                        Balance sheet total - advances received



Net interest-bearing liabilities      = Interest-bearing liabilities - cash and
                                        cash equivalents



Net gearing ratio, %                  = (Interest-bearing liabilities - cash and
                                        cash equivalents)x 100/      -----------------------------------------
                                        Equity



Earnings per share                    = Profit/loss for the period attributable
                                        to  equity holders of the parent
                                        company/
                                       -----------------------------------------
                                        Adjusted weighted average number of
                                        shares in issue during the period



Equity per share                      = Equity attributable to equity holders of
                                        the parent company/
                                       -----------------------------------------
                                        Adjusted number of shares at the end of
                                        the period



Dividend per share                    = Dividend for the period/
                                       -----------------------------------------
                                        Adjusted number of shares at the end of
                                        the period



Effective dividend yield, %           = Dividend per share x 100/
                                       -----------------------------------------
                                        Trading price at the end of the period



Price/earnings ratio (P/E)            = Last adjusted trading price at the end
                                        of the period/
                                       -----------------------------------------
                                        Earnings per share



Average trading price                 = Total traded amount in euro/
                                       -----------------------------------------
                                        Adjusted number of shares traded during
                                        the period



Market capitalisation at the end of   = Number of shares at the end of the
the period                              period x trading price at the end of the
                                        period



Trading volume                        = Number of shares traded during the
                                        period/
                                       -----------------------------------------
                                        Weighted average number of shares during
                                        the period





All figures of the financial tables are rounded, and consequently the sum of
individual figures can deviate from the presented sum figure.

The figures are unaudited. In the written report, the figures in parenthesis
refer to the corresponding period in the previous year.

The future estimates and forecasts in this interim report are based on company
management´s current knowledge. Actual events and results may differ from the
estimates presented here.

PRESS CONFERENCE

The company´s press conference for the media and analysts will be held on
Thursday, 29 April 2010 at 9.00 a.m. at Helsinki World Trade Center,
Aleksanterinkatu 17, second floor, Helsinki. In the conference, Okmetic´s
President Kai Seikku will present the group´s development in January-March 2010
and prospects for 2010.

We ask participants to kindly give advance notice of their attendance by email
at communications@okmetic.com or by telephone to +358 9 5028 0406/Marika
Mäntymaa.

OKMETIC OYJ

Board of directors

For further information, please contact:

President Kai Seikku, Okmetic Oyj,
tel. +358 9 5028 0232, email: kai.seikku@okmetic.com

Senior Vice President, Finance Esko Sipilä, Okmetic Oyj,
tel. +358 9 5028 0286, email: esko.sipila@okmetic.com

Distribution:
NASDAQ OMX Helsinki
Principal media
www.okmetic.com <http://www.okmetic.com/>

OKMETIC IN BRIEF

Take it higher

Okmetic is a technology company which supplies tailor-made silicon wafers for
sensor and semiconductor industries and sells its technological expertise to the
solar cell industry. Okmetic provides its customers with solutions that boost
their competitiveness and profitability.

Okmetic's silicon wafers are part of a further processing chain that produces
end products that improve human interaction and quality of life. Okmetic's
products are based on high-tech expertise that generates added value for
customers, innovative product development and an extremely efficient production
process.

Okmetic has a global customer base and sales network, production plants in
Finland and the US and contract manufacturers in Japan and China. Okmetic's
shares are listed on NASDAQ OMX Helsinki under the code OKM1V. For more
information on the company, please visit our website at www.okmetic.com.



[HUG#1409271]

OKME1310.pdf